CapsoVision Inc. Submits FDA 510(k) Application, Shares Surge 8.4%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy AXTI?
Source: Benzinga
- Stock Surge: CapsoVision, Inc. submitted its 510(k) application for the proprietary AI-assisted CapsoCam Plus module, resulting in an 8.4% increase in share price to $12.55 on Tuesday, indicating strong market confidence in its innovative technology.
- Successful Public Offering: AXT, Inc. priced its public offering at $12.25 per share, raising $87 million, which led to a 13.5% rise in its stock price to $16.56, reflecting investor recognition of its growth potential.
- Analyst Rating Upgrade: HC Wainwright & Co. maintained a Buy rating on Greenwich LifeSciences, Inc. and raised the price target from $39 to $50, contributing to a 13.6% increase in its stock price to $28.25, showcasing market optimism regarding its product prospects.
- Clinical Trial Update: SELLAS Life Sciences Group, Inc. provided an update on its Phase 3 REGAL trial for acute myeloid leukemia, resulting in a 12% increase in its stock price to $3.7537, indicating potential breakthroughs in treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXTI
Wall Street analysts forecast AXTI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXTI is 16.20 USD with a low forecast of 7.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.430
Low
7.00
Averages
16.20
High
26.00
Current: 20.430
Low
7.00
Averages
16.20
High
26.00
About AXTI
AXT, Inc. is a material science company that develops and manufactures high-performance compound and single element semiconductor wafer substrates comprising indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge). Its wafer substrates are used when a typical silicon wafer substrate cannot meet the performance requirements of a semiconductor or optoelectronic device. It has two product lines: specialty material substrates and raw materials integral to these substrates. Its InP is a semiconductor wafer substrate used in broadband and fiber optic applications, 5G infrastructure and data center connectivity. Its semi-conducting GaAs substrates are used to create opto-electronic products, including high brightness light emitting diodes that are often used to backlight wireless handsets and LCD televisions and for automotive, signage, and lighting applications. Its Ge substrates are used in applications, such as solar cells for space and terrestrial photovoltaic applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maytree Asset Management Acquires 682,299 Shares in AXT
- Holding Update: According to a SEC filing dated February 3, 2026, Maytree Asset Management Ltd reported a new holding of 682,299 shares in AXT (AXTI) during Q4, with an estimated transaction value of $11.16 million, reflecting the firm's bullish outlook on AXT.
- Asset Allocation Shift: This acquisition positions AXT to account for 8.27% of Maytree's 13F reportable assets, highlighting its significance in the firm's portfolio, especially amid strong performance in tech stocks.
- Impressive Stock Performance: As of February 2, 2026, AXT's share price stood at $20.94, soaring 911.6% over the past year, significantly outperforming the S&P 500 by 886.42 percentage points, indicating optimistic market expectations for its future growth.
- Market Outlook Analysis: Although AXT reported an operating loss of $1.1 million in Q3, an improvement from a $3.4 million loss the previous year, Maytree's purchase may be driven by anticipated growth in the AI market, despite the current price-to-sales ratio nearing multi-year highs, suggesting investors should proceed with caution.
See More
Maytree Acquires 682,299 Shares of AXT, Valued at $11.16 Million
- New Position Established: Maytree Asset Management acquired 682,299 shares of AXT in Q4 2026, with an estimated transaction value of $11.16 million, indicating a bullish outlook on AXT's future growth potential.
- Position Value Increase: The quarter-end value of this new position also stood at $11.16 million, reflecting both the impact of the purchase and price movements, which propelled AXT into Maytree's top five holdings, enhancing portfolio diversification.
- Outstanding Stock Performance: As of February 2, 2026, AXT shares were priced at $20.94, representing a staggering 911.6% increase year-over-year, significantly outperforming the S&P 500 by 886.42 percentage points, showcasing strong market demand.
- Optimistic Industry Outlook: AXT's semiconductor components have seen increased demand due to the booming AI market; although the company reported an operating loss of $1.1 million in Q3, this was an improvement from a $3.4 million loss the previous year, indicating potential in the AI sector.
See More
AXT Inc Shares Surpass Analyst Target Price of $18.12
- Price Target Breakthrough: AXT Inc's stock recently reached $18.54 per share, surpassing the analyst-set 12-month target price of $18.12, indicating a positive market sentiment that may prompt analysts to reassess their target prices.
- Analyst Target Variability: Within the Zacks coverage universe, AXT Inc's target prices show significant variability, with a low of $8.50 and a high of $26.00, resulting in a standard deviation of $7.261, reflecting differing expectations about the company's future performance.
- Investor Signal: The stock's rise above the average target price provides investors with a signal to reassess the company, prompting them to consider whether the current valuation is justified or if it might be time to take profits in light of potential market fluctuations.
- Analyst Rating Overview: AXT Inc's analyst ratings range from 1 to 5, with 1 being a strong buy and 5 a strong sell, offering investors a diverse perspective on the company's future performance, aiding them in making more informed investment decisions.
See More
Morgan Stanley Downgrades Domino's Pizza to Equal-Weight, Price Target Cut to $455
- Domino's Pizza Downgrade: Morgan Stanley analyst Brian Harbour downgraded Domino's Pizza (NASDAQ:DPZ) from Overweight to Equal-Weight, lowering the price target from $535 to $455, reflecting caution about future growth, as shares closed at $400.28 on Friday, indicating market concerns about the company's outlook.
- AXT Inc Rating Change: Needham analyst Charles Shi downgraded AXT Inc (NASDAQ:AXTI) from Buy to Hold, reflecting diminished confidence in its market performance, with shares closing at $22.09 on Friday, signaling investor caution regarding its future prospects.
- Philip Morris Rating Adjustment: Jefferies analyst Edward Mundy downgraded Philip Morris International Inc. (NYSE:PM) from Buy to Hold and cut the price target from $220 to $180, with shares closing at $173.62 on Friday, indicating market worries about its growth potential.
- ConocoPhillips Rating Maintained: JP Morgan analyst Arun Jayaram downgraded ConocoPhillips (NYSE:COP) from Overweight to Neutral while maintaining a price target of $98, with shares closing at $98.19 on Friday, reflecting cautious sentiment in the market regarding its future performance.
See More
Semiconductor Shares Rise 3.4%, Led by AXTI's 15.6% Gain
- Sector Performance: On Thursday, semiconductor shares collectively rose by approximately 3.4%, indicating strong market confidence in the sector, which may reflect investor optimism about future growth prospects.
- AXTI's Surge: AXTI's stock price increased by about 15.6%, making it the top performer of the day, suggesting its competitive strength in the market and investor confidence in its future earnings.
- Entegris Growth: Entegris saw its stock rise by approximately 11%, further solidifying its critical position in the semiconductor supply chain, potentially attracting more investor interest in its business developments.
- Market Trend Analysis: The robust performance of semiconductor stocks may signal a recovery in the tech sector, prompting investors to monitor the financial performance and market dynamics of related companies to seize potential investment opportunities.
See More
Boston Scientific Acquires Penumbra at $374 per Share
- Acquisition Deal: Boston Scientific has agreed to acquire Penumbra at $374 per share, valuing the transaction at approximately $14.5 billion, indicating strong interest in the medical device market and expected to enhance Boston Scientific's product portfolio and market share.
- Shareholder Options: Penumbra shareholders can choose between cash or Boston Scientific stock, with an overall proration of about 73% cash and 27% equity, which may attract more investor participation and enhance shareholder satisfaction.
- Strong Performance: Penumbra's preliminary fourth-quarter results exceeded expectations, with shares rising 12.1% to $351.25 on Thursday, reflecting market confidence in its future growth potential and likely boosting investor sentiment further.
- Market Reaction: The acquisition news significantly boosted Penumbra's stock price, demonstrating a positive market response to M&A activities in the healthcare sector, which may also trigger similar acquisition activities among other related companies, further energizing the market.
See More
Maytree Asset Management Acquires 682,299 Shares in AXT
- Holding Update: According to a SEC filing dated February 3, 2026, Maytree Asset Management Ltd reported a new holding of 682,299 shares in AXT (AXTI) during Q4, with an estimated transaction value of $11.16 million, reflecting the firm's bullish outlook on AXT.
- Asset Allocation Shift: This acquisition positions AXT to account for 8.27% of Maytree's 13F reportable assets, highlighting its significance in the firm's portfolio, especially amid strong performance in tech stocks.
- Impressive Stock Performance: As of February 2, 2026, AXT's share price stood at $20.94, soaring 911.6% over the past year, significantly outperforming the S&P 500 by 886.42 percentage points, indicating optimistic market expectations for its future growth.
- Market Outlook Analysis: Although AXT reported an operating loss of $1.1 million in Q3, an improvement from a $3.4 million loss the previous year, Maytree's purchase may be driven by anticipated growth in the AI market, despite the current price-to-sales ratio nearing multi-year highs, suggesting investors should proceed with caution.
See More
Maytree Acquires 682,299 Shares of AXT, Valued at $11.16 Million
- New Position Established: Maytree Asset Management acquired 682,299 shares of AXT in Q4 2026, with an estimated transaction value of $11.16 million, indicating a bullish outlook on AXT's future growth potential.
- Position Value Increase: The quarter-end value of this new position also stood at $11.16 million, reflecting both the impact of the purchase and price movements, which propelled AXT into Maytree's top five holdings, enhancing portfolio diversification.
- Outstanding Stock Performance: As of February 2, 2026, AXT shares were priced at $20.94, representing a staggering 911.6% increase year-over-year, significantly outperforming the S&P 500 by 886.42 percentage points, showcasing strong market demand.
- Optimistic Industry Outlook: AXT's semiconductor components have seen increased demand due to the booming AI market; although the company reported an operating loss of $1.1 million in Q3, this was an improvement from a $3.4 million loss the previous year, indicating potential in the AI sector.
See More
AXT Inc Shares Surpass Analyst Target Price of $18.12
- Price Target Breakthrough: AXT Inc's stock recently reached $18.54 per share, surpassing the analyst-set 12-month target price of $18.12, indicating a positive market sentiment that may prompt analysts to reassess their target prices.
- Analyst Target Variability: Within the Zacks coverage universe, AXT Inc's target prices show significant variability, with a low of $8.50 and a high of $26.00, resulting in a standard deviation of $7.261, reflecting differing expectations about the company's future performance.
- Investor Signal: The stock's rise above the average target price provides investors with a signal to reassess the company, prompting them to consider whether the current valuation is justified or if it might be time to take profits in light of potential market fluctuations.
- Analyst Rating Overview: AXT Inc's analyst ratings range from 1 to 5, with 1 being a strong buy and 5 a strong sell, offering investors a diverse perspective on the company's future performance, aiding them in making more informed investment decisions.
See More
Morgan Stanley Downgrades Domino's Pizza to Equal-Weight, Price Target Cut to $455
- Domino's Pizza Downgrade: Morgan Stanley analyst Brian Harbour downgraded Domino's Pizza (NASDAQ:DPZ) from Overweight to Equal-Weight, lowering the price target from $535 to $455, reflecting caution about future growth, as shares closed at $400.28 on Friday, indicating market concerns about the company's outlook.
- AXT Inc Rating Change: Needham analyst Charles Shi downgraded AXT Inc (NASDAQ:AXTI) from Buy to Hold, reflecting diminished confidence in its market performance, with shares closing at $22.09 on Friday, signaling investor caution regarding its future prospects.
- Philip Morris Rating Adjustment: Jefferies analyst Edward Mundy downgraded Philip Morris International Inc. (NYSE:PM) from Buy to Hold and cut the price target from $220 to $180, with shares closing at $173.62 on Friday, indicating market worries about its growth potential.
- ConocoPhillips Rating Maintained: JP Morgan analyst Arun Jayaram downgraded ConocoPhillips (NYSE:COP) from Overweight to Neutral while maintaining a price target of $98, with shares closing at $98.19 on Friday, reflecting cautious sentiment in the market regarding its future performance.
See More
Semiconductor Shares Rise 3.4%, Led by AXTI's 15.6% Gain
- Sector Performance: On Thursday, semiconductor shares collectively rose by approximately 3.4%, indicating strong market confidence in the sector, which may reflect investor optimism about future growth prospects.
- AXTI's Surge: AXTI's stock price increased by about 15.6%, making it the top performer of the day, suggesting its competitive strength in the market and investor confidence in its future earnings.
- Entegris Growth: Entegris saw its stock rise by approximately 11%, further solidifying its critical position in the semiconductor supply chain, potentially attracting more investor interest in its business developments.
- Market Trend Analysis: The robust performance of semiconductor stocks may signal a recovery in the tech sector, prompting investors to monitor the financial performance and market dynamics of related companies to seize potential investment opportunities.
See More
Boston Scientific Acquires Penumbra at $374 per Share
- Acquisition Deal: Boston Scientific has agreed to acquire Penumbra at $374 per share, valuing the transaction at approximately $14.5 billion, indicating strong interest in the medical device market and expected to enhance Boston Scientific's product portfolio and market share.
- Shareholder Options: Penumbra shareholders can choose between cash or Boston Scientific stock, with an overall proration of about 73% cash and 27% equity, which may attract more investor participation and enhance shareholder satisfaction.
- Strong Performance: Penumbra's preliminary fourth-quarter results exceeded expectations, with shares rising 12.1% to $351.25 on Thursday, reflecting market confidence in its future growth potential and likely boosting investor sentiment further.
- Market Reaction: The acquisition news significantly boosted Penumbra's stock price, demonstrating a positive market response to M&A activities in the healthcare sector, which may also trigger similar acquisition activities among other related companies, further energizing the market.
See More
